Local Institution

Oviedo 33011

0 studies enrolling now · 9 studies all time

What they study most

Acute Coronary Syndrome (ACS), Arthritis, Rheumatoid, Chronic Hepatitis B, Diabetes Mellitus II, Leukemia, Liver Cancer, Melanoma, Metabolics Diabetes Nos, Myeloid Leukemia, Chronic

Studies at this site

• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants — Withdrawn before enrolling
• Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment — Completed
• Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
• Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) — Stopped early
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia — Completed
• Safety Study of Apixaban in Recent Acute Coronary Syndrome — Completed
• Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients — Completed
• Dose Ranging Study With LT, Monotherapy, PPAR — Completed
• PPAR-COMBO With Sulfonylurea — Completed